Download - Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E
![Page 1: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/1.jpg)
Development and application of mutation
specific antibodies: from IDH1-R132H to BRAF-V600E
Andreas von Deimling
![Page 2: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/2.jpg)
Under a licensing agreement between DIANOVA GmbH, Hamburg,
Germany and the German Cancer Research Center,
and
under a licensing agreement between Roche, Tucson, USA and the
German Cancer Research Center,
Dr. von Deimling is entitled to a share of royalties received by the
German Cancer Research Center on sales of H09 and VE1 antibody.
The terms of this arrangement are being managed by the German
Cancer Research Center in accordance with its conflict of interest
policies.
Disclosures
![Page 3: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/3.jpg)
Early molecular pathologists
![Page 4: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/4.jpg)
isocitrate dehydrogenases
IDH1 cytosolic NADP+ specific
IDH2 mitochondrial NADP+ specific
IDH3A / IDH3B / IDH3G mitochondrial NAD+ specific
![Page 5: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/5.jpg)
Gene Nucleotide change
Amino acid change
N (%)
IDH1 (716) G395A R132H 664 (92.7%)
C394T R132C 29 (4.2%)
C394A R132S 11 (1.5%)
C394G R132G 10 (1.4%)
G395T R132L 2 (0.2%)
IDH2 (31) G515A R172K 20 (64.5%)
G515T R172M 6 (19.3%)
A514T R172W 5 (16.2%)
IDH1 IDH2 1010 diffuse gliomas
![Page 6: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/6.jpg)
IDH1-R132H mutation
![Page 7: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/7.jpg)
Enzyme activity of Isocitrat-dehydrogenase (IDH1)
0.000
0.050
0.100
0.150
0.200
0.250
0.300
0.350
0.400
0.450
0.500
0 5 10 15 20 25 30 35 40 45
untr.
wt
H
E
Q
S
C
V
L
G
GFP
![Page 8: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/8.jpg)
C OH H
NADP+ NADPH
H
CO2
COO-
CH2
COO-
C COO- H
C O
COO-
CH2
COO-
C COO- H
COO-
CH2
COO-
C H H
C O
isocitrate oxalosuccinate a-ketoglutarate (2-oxoglutarate)
wt IDH
2-hydroxyglutarate
COO-
CH2
COO-
C OH
CH2
H
a-ketoglutarate (2-oxoglutarate)
NADPH NADP+ COO-
CH2
COO-
C O
CH2
mut
![Page 9: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/9.jpg)
0
10
20
30
40
50
60
70
80
90
100
IDH1 wt IDH1R132H
IDH1R132C
IDH1R132G
IDH1R132S
IDH1R132L
IDH2 wt IDH2R172K
frequ
ency
1
10
100
1000
10000
nmol
2-H
G/m
g to
tal p
rote
in
% of total IDH mutations in glioma2-HG concentration in cell pellet
IDH1 mutants
2-HG concentrations inversely correlate with the frequency of IDH mutation occurrence
![Page 10: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/10.jpg)
David
![Page 11: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/11.jpg)
mIDH1R132H H09
rIDH1
55 kD
36 kD
72 kD
1 3 2 4 5 3 2 4 5 1
Mouse monoclonal H09 Antibody (IDH1R132H)
![Page 12: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/12.jpg)
![Page 13: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/13.jpg)
Pilocytic astrocytoma
Oligodendroglioma III Clear cell ependymoma Central neurocytoma
DNT Oligodendroglioma II
![Page 14: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/14.jpg)
![Page 15: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/15.jpg)
![Page 16: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/16.jpg)
![Page 17: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/17.jpg)
![Page 18: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/18.jpg)
![Page 19: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/19.jpg)
GBM – A III cohort and prognostic parameters
Months 0 12 24 36 48 60 72 84 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
p<0.0001 Months 0 12 24 36 48 60 72 84 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
p<0.0001
A III (n=145) GBM (n=237) IDH wt (n=278)
IDH mut (n=104)
Months 0 12 24 36 48 60 72 84 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
p<0.0001 Months 0 12 24 36 48 60 72 84 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
p<0.0001
MGMT not meth (n=170) MGMT meth (n=168) Age <= 60 (n=225)
Age > 60 (n=157)
Histology IDH1 status
Age MGMT status
382 patients NOA04 and GGN overall survival
![Page 20: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/20.jpg)
GBM – A III and IDH1 status
Months
0 12 24 36 48 60 72 84 0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
p<0.0001
A III & IDH mut
(n=58) GBM & IDH mut (n=17) A III & IDH wt
GBM & IDH wt (n=220)
(n=87)
overall survival
![Page 21: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/21.jpg)
GBM – A III and IDH1 status
Age > 60
Months
0 12 24 36 48 60 72 84
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
p=0.457
(n=22) A III & IDH wt
GBM & IDH wt (n=124)
overall survival
![Page 22: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/22.jpg)
0 12 24 36 48 60 72 84 0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
p<0.0001
A III & IDH mut
(n=58) GBM & IDH mut (n=17) A III & IDH wt
GBM & IDH wt (n=220)
(n=87)
Months
GBM – A III and IDH1 status
progression free survival
![Page 23: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/23.jpg)
Structure of IDH1
NADP+
Isocitrate
Homodimer(E.coli) Mesecar et al.(1997)
Mesecar et al. (1997)
![Page 24: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/24.jpg)
http://fightcolorectalcancer.org
![Page 25: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/25.jpg)
Pilocytic astrocytoma
![Page 26: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/26.jpg)
Green = BRAF Red = KIAA1549
BRAF/KIAA1549 - duplication and fusion in pilocytic astrocytoma
![Page 27: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/27.jpg)
BRAF
Michaloglou et al. 2008
T599 and S602 phosphorylation activate BRAF BRAF V600E mutation mimicks phosphorylation and leads to constitutive activity
![Page 28: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/28.jpg)
BRAF V600 mutations in human tumors
In up to 5-7% of all human tumors ~95% BRAF V600E Carcinomas
• thyroid cancer (~30-50%) (papillary and anaplastic) • colorectal cancer (~5-10%) • ovarian carcinoma (~30% in serous forms)
Skin tumors
• malignant melanoma (~60%) Hematologic tumors
• Hairy cell leukemia (>90%) • Langerhans cell histiocytosis (~50%)
Primary brain tumors
• pleomorphic xanthoastrocytoma (~60%) • ganglioglioma (~20%) • pilocytic astrocytoma (~5-10%) (mostly BRAF-KIAA1549 fusion)
![Page 29: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/29.jpg)
BRAF V600E inhibitors
Selective small - molecule BRAFV600E inhibitors
Vemurafenib (Zelboraf™) Flaherty NEJM 2010, Chapman NEJM 2011 FDA approval for advanced melanoma (08/2011)
GSK2118436 Long, ESMO 2010
![Page 30: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/30.jpg)
![Page 31: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/31.jpg)
BRAF V600E antibody (VE1)
![Page 32: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/32.jpg)
Antibody confirmation by sequencing of 85 tumors
Match in 97%
![Page 33: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/33.jpg)
Papillary Thyroid Carcinoma
Koperek et al.
N
VE1 pos
VE1 neg
total 144 76 (53%) 68 (47%)
Papillary micro-adenoma <1cm 72 42 30
Papillary macro-adenoma >1cm 72 34 38
BRAF V600E
BRAF wt
verified by sequencing
39 VE1 pos
39 0
Bullock et al.
N VE1 pos VE1 neg
total 96 68 (71%) 28 (29%)
BRAF V600E BRAF wt
verfied by sequencing
96 56 (61%) 37 (39%)
Koperek et al. Am J. Surg Pathol 2012 Bullock et al. Endocr Relat Cancer 2012
![Page 34: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/34.jpg)
Papillary Thyroid Carcinoma
Koperek et al. Am J. Surg Pathol 2012 Bullock et al. Endocr Relat Cancer 2012
![Page 35: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/35.jpg)
Papillary Thyroid Carcinoma
![Page 36: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/36.jpg)
Ovarian Carcinoma Bösmüller et al.
N VE1 pos VE1 neg
total 179 23 (13%) 156 (87%)
Serous ovarian borderline tumor 31 22 (71%) 9 (29%)
Serous ovarian carcinoma G1 7 1 6
Serous ovarian carcinoma G3 141 0 141 (100%)
BRAF V600E
BRAF wt
verified by sequencing
23 VE1 pos
21 2 (low tumor
fraction)
Preusser et al.
N VE1 pos VE1 neg
total 144 7 (5%) 137 (95%)
Serous ovarian borderline tumor
31 4 27
Serous ovarian carcinoma G1 15 3 12
Serous ovarian carcinoma G3 44 0 44
BRAF V600E BRAF wt
verfied by sequencing
6 VE1 pos
6 0
Bösmüller et al. Hum Pathol 2013 Preusser et al. Appl Immunhistochem Mol Morphol 2013
![Page 37: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/37.jpg)
Ovarian Carcinoma
Bösmüller et al. Hum Pathol 2013 Preusser et al. Appl Immunhistochem Mol Morphol 2013
Borderline tumor grade 3
Serous ovarian carcinoma grade 1
Serous ovarian carcinoma grade 1
Borderline tumor grade 3
![Page 38: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/38.jpg)
Histiocytoses Sahm et al.
N
VE1 pos
VE1 neg
Langerhans Cell Histiocytosis
89 34 (38%) 55 (62%)
BRAF V600E
BRAF wt
verified by sequencing
46 select
ed
Concordance of IHC and
sequencing was 96%
Haroche et al.
N BRAF V600E BRAF wt
total 127 7 (5%) 137 (95%) Langerhans Cell Histiocytosis
29 11 (38%) 18 (62)
Erdheim Chester disease 24 13 (54%) 11 (46%)
Juvenile Xanthogranuloma 12 0 23
Rosai Dorfman disease 23 0 23
VE1 pos
VE1 neg
verfied by sequencing
7 select
ed
Concordance of IHC and sequencing was 100%
Sahm et al. Blood 2012 Haroche et al. Blood 2013
![Page 39: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/39.jpg)
Histiocytoses
Sahm et al. Blood 2012 Haroche et al. Blood 2013
Langerhans Cell Histiocytosis VE1
Erdheim Chester Disease VE1
Erdheim Chester Disease VE1
Langerhans Cell Histiocytosis S100
![Page 40: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/40.jpg)
BRAF V600E
S100
CD1a
CD207
Eosinophilic Granuloma
![Page 41: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/41.jpg)
Hairy Cell Leukemia
Andrulis et al. N
VE1 pos
VE1 neg
total 52 76 (53%) 68 (47%)
Hairy cell leukemia 32 32 (100%) 0
Spleenic lymphoma/leukemia unclassifiable 6 0 6
Splenic marginal zone lymphoma 8 0 8
BRAF V600E
BRAF wt
verified by sequencing
30 VE1 pos 28 2
Andrulis et al. Am J. Surg Pathol 2012
UltraView OptiView
![Page 42: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/42.jpg)
Hairy Cell Leukemia
VE1 (BRAF V600E)
![Page 43: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/43.jpg)
Gastro-esophageal cancer
Preusser et al.
N VE1 pos
total 534 0
esophageal squamous cell carcinoma 119 0
esophageal adenocarcinoma 72 0
GEJ / cardia 63 0
gastric cancer (corpus / antrum) 199 0
gastric GIST 81 0
Preusser et al. Appl Immunohistochem 2013
![Page 44: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/44.jpg)
Lung adenocarcinoma Ilie et al.
N VE1 pos
VE1 neg
Total
450 (wt for
EGFR, KRAS, Pi3Ka, Her 2, ALK-EML4)
19 (4%) 231 (96%)
acinar 285 5 (*) 280
papillary 142 5 (*) 137
micropapillary 10 9 1
other 13 0 13
BRAF V600E
BRAF wt
verified by sequencing
450 21 429
Ilie et al. Ann Oncol 2013
lung acinar adeno-carcinoma
VE1 staining absent
![Page 45: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/45.jpg)
Melanoma
Long et al.
N VE1 pos
VE1 neg
melanoma 97 38 59
VE1 missed 11 other BRAF mutations
5 discrepant cases between VE1 and V600E sequencing data in 3 cases initial testing was false positive in 1 case initial testing was false negative in 1 case VE1 was false negative
BRAF V600E
BRAF wt
verified by sequencing
97 38 (*+11) 48
Busam et al.
N VE1 pos
VE1 neg
total 44 7 (5%) 137 (95%) metastatic melanomas with BRAF V600E (DNA sequencing)
22 22 0
metastatic melanomas without BRAF V600E (DNA sequencing)
22 0 22
Inhomogenous in some staining raises the question of response to targeting drugs
Long et al. Am J Surg Pathol 2013 Preusser et al. Appl Immunhistochem Mol Morphol 2013
![Page 46: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/46.jpg)
Melanoma at primary site
![Page 47: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/47.jpg)
Melanoma metastasis to lymph node (repeatedly sequenced BRAF wt)
![Page 48: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/48.jpg)
Melanoma
Wilmott et al.
VE1 intensity
melanomas with BRAF V600E (DNA sequencing)
Treated with BRAF inhibitors
36 strong
20 moderate
2 weak
Inhomogenous in some staining raises the question of response to targeting drugs
Wilmott et al. B J Cancer 2013
![Page 49: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/49.jpg)
Serrated lesions and polyps of the colon
Mesteri et al.
N
VE1 pos
total 115 79
Sessile serrated adenoma 38 38 (100%)
Traditional serrated adenoma 16 15 (93%)
Microvesicular hyperplastic polyp
44 26 (59%)
Goblet-cell rich hyperplastic polyp 17 0
Mesteri et al. submitted Sessile serrated adenoma
Microvesicular hyperplastic polyp
![Page 50: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/50.jpg)
Colon carcinoma
![Page 51: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/51.jpg)
Lynch Syndrome in colorectal cancer
Toon et al. in press Capper et al. submitted
Recognition of Lynch syndrome requires detection of high level microsatellite instability (MSI-H).
Most tumors with MSH-I are sporadic. Therefore germline mutation analysis is required BRAFV600E in MSI CRC excludes Lynch Syndrome
![Page 52: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/52.jpg)
Pleomorphic xanthoastrocytoma
![Page 53: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/53.jpg)
Pleomorphic xanthoastrocytoma
VE1 (BRAF V600E)
Pan- BRAF
![Page 54: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/54.jpg)
glioblastoma with BRAF V600E mutation
VE1
GBM BRAF wt
GBM BRAF V600E
VE1
![Page 55: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/55.jpg)
Ganglioglioma
VE1 (BRAF V600E)
![Page 56: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/56.jpg)
Ganglioglioma
![Page 57: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/57.jpg)
BRAF V600E in 874 brain metastases
Melanoma 42/76 (55.3%)
Ovarian cancer 1/15 (6.7%)
Lung cancer 1/355 (0.3%)
Thyroid cancer 2/6
Colorectal cancer 4/72 (5.5%)
Chorioncarcinoma 1/2
![Page 58: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/58.jpg)
BRAF V600E
melanoma
Lynch syndrome
papillary thyroid
carcinoma
Colon carcinoma
Serrated adenoma
hairy cell leukemia
Langerhans cell
histiocytosis
Erdheim Chester disease
Ovarian carcinoma
PXA
GG
Glio-blastoma
![Page 59: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/59.jpg)
Antibodies targeting IDH1 and BRAF Mutations
- tumor specific - diagnostic relevance
- stratify tumor patients for targeted therapy
![Page 60: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/60.jpg)
![Page 61: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/61.jpg)
Jörg Balss David Capper Andreas von Deimling Antje Habel Christian Hartmann Christian Kölsche Andrey Korshunov Jochen Meyer Stefan Pusch Felix Sahm Genevieve Schindler
Peter Birner Matthias Preusser Ildiko Mesteri Mindaugas Andrulis Julien Haroche Hans Bösmüller Oskar Koperek Georgina Long Christopher Toon Marcel Ilie Klaus Busam Jams Wilmott Alexander Sorokhod Boris Bastian
Hanswalter Zentgraf
Group and Cooperation Partners
David Capper
For the German Glioma Net: Michael Weller
![Page 62: Development and Application of Mutation Specific Antibodies: from IDH1-R132H to BRAF-V600E](https://reader034.vdocuments.us/reader034/viewer/2022050808/54c2312b4a79596d658b4580/html5/thumbnails/62.jpg)
Thank you !